Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024

医薬品有効成分(API)の世界市場予測(~2024年)

◆タイトル:Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024
◆商品コード:PH 1262
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年1月7日
◆ページ数:254
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

医薬品有効成分(API)の世界市場は、2019年の1,822億米ドルから2024年には2,452億米ドルに達し、この期間中6.1%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、慢性疾患の発生率の増加、ジェネリック医薬品の重要性の高まり、およびバイオ医薬品に対する理解の増加が考えられます。特に、商用における使用が主な用途です。航空機への複合材料の使用の増加と機体数の増加は、今後5年間でこの市場の成長を促進すると予想されます。一方で、市場に不利な医薬品価格管理政策と偽造医薬品の蔓延は、この市場の成長を抑制すると予想されます。当調査レポートでは、医薬品有効成分(API)の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類別(革新的API、ジェネリックAPI)分析、メーカー別(キャプティブ、マーチャント)分析、合成別(合成、バイオテクノロジ)分析、製品別(mAb、ホルモン、バイオシミラー)分析、医薬品有効成分(API)の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Increasing incidence of chronic diseases and technological advancements in API manufacturing are expected to drive the overall growth of the global APIs market.”The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

“The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.”

On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in demand for monoclonal antibodies, and their similarity with the natural biological compounds found in the human body influence the growth of this segment.

“The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market.”

Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the biotech APIs market. Factors such as the increasing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and reduced side effects as compared to chemotherapy are responsible for driving this market.

“North America to dominate the market during the forecast period.”

In 2019, North America is expected to dominate the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 37%, Tier 2: 22%, Tier 3: 41%
• By Designation – C-level: 25%, D-level: 20%, Others: 55%
• By Region – North America: 40%, Europe: 27%, Asia: 20%, RoW: 13%

List of Companies Profiled in the Report
• Pfizer, Inc. (US)
• Novartis AG (Switzerland)
• Sanofi (France)
• Boehringer Ingelheim (Germany)
• Bristol-Myers Squibb (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Eli Lilly and Company (US)
• GlaxoSmithKline plc (UK)
• Merck & Co., Inc. (US)
• AbbVie Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AstraZeneca plc (UK)

Research Coverage:
This report provides a picture of the global APIs market. It aims at estimating the size and future growth potential of the market across different segments, such as type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them the closest approximations of the revenue numbers for the overall APIs market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY SOURCES 31
2.1.1.1 Key Data from Secondary Sources 31
2.1.2 PRIMARY SOURCES 32
2.1.2.1 Key Data from Primary Sources 33
2.1.2.2 Key Industry Insights 34
2.2 MARKET SIZE ESTIMATION 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 37
2.4 MARKET SHARE ESTIMATION 38
2.5 ASSUMPTIONS FOR THE STUDY 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 44
4.1 ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW 44
4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 45
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 45
4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 46
4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 47
4.6 GEOGRAPHIC SNAPSHOT: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
5.2.1 DRIVERS 49
5.2.1.1 Increasing incidence of chronic diseases 49
5.2.1.2 Technological advancements in API manufacturing 50
5.2.1.3 Growing importance of generics 50
5.2.1.4 Increasing uptake of biopharmaceuticals 51
5.2.1.5 Growing adoption of artificial intelligence-based tools for drug discovery 52
5.2.1.6 Adoption of organ-on-chip models in drug development 53
5.2.1.7 Growing focus on precision medicine 53
5.2.1.8 Growing investments in real-world evidence by pharmaceutical companies 54
5.2.2 RESTRAINTS 55
5.2.2.1 Unfavorable drug price control policies across various countries 55
5.2.2.2 Increasing penetration of counterfeit drugs 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Emerging biosimilars market 56
5.2.3.2 Highly potent active pharmaceutical ingredients 56
5.2.3.3 Emerging markets 57
5.2.3.4 Emerging technologies 57
5.2.4 CHALLENGES 57
5.2.4.1 Product differentiation – A major concern for API manufacturers 57
5.2.4.2 High manufacturing costs 58
6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 59
6.1 INTRODUCTION 60
6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 61
6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVAL TO DRIVE MARKET GROWTH 61
6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 63
6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH 63
7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 64
7.1 INTRODUCTION 65
7.2 CAPTIVE API MANUFACTURERS 66
7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY HAVE DRIVEN FOCUS ON CAPTIVE MANUFACTURING 66
7.3 MERCHANT API MANUFACTURERS 67
7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE 68
7.3.1.1 Merchant Innovative API Manufacturers 69
7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain market growth 69
7.3.1.2 Merchant Generic API Manufacturers 70
7.3.1.2.1 Low manufacturing cost of generics likely to drive the growth of this segment 70

7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 70
7.3.2.1 Merchant Synthetic API Manufacturers 71
7.3.2.1.1 Need for specialized manufacturing capabilities has resulted in expansion among market players in this segment 71
7.3.2.2 Merchant Biotech API Manufacturers 72
7.3.2.2.1 Complexity of manufacturing biotech APIs has driven focus on partnerships between companies and CMOs 72
8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 74
8.1 INTRODUCTION 75
8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 76
8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 77
8.2.1.1 Innovative synthetic APIs 77
8.2.1.1.1 The high value of innovative APIs to drive the growth of this segment 77
8.2.1.2 Generic synthetic APIs 78
8.2.1.2.1 Initiatives to promote the penetration of generics to bring down healthcare costs—a major growth driver 78
8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 79
8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 81
8.3.1.1 Innovative biotech APIs 81
8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the market for this segment 81
8.3.1.2 Generic biotech APIs 82
8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment 82
8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 84
8.3.2.1 Monoclonal antibodies 85
8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment 85
8.3.2.2 Hormones & growth factors 86
8.3.2.2.1 The growing incidence of hormonal disorders to drive the market for this segment 86
8.3.2.3 Cytokines 87
8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment 87
8.3.2.4 Fusion proteins 88
8.3.2.4.1 Growing applications of Fc fusion proteins in biopharmaceuticals to drive the growth of this segment 88
8.3.2.5 Recombinant vaccines 89
8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development—a positive indicator of growth 89
8.3.2.6 Therapeutic enzymes 90
8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive the growth of this segment 90
8.3.2.7 Blood factors 90
8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment 90
8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 91
8.3.3.1 Mammalian expression systems 92
8.3.3.1.1 Ability of these systems to carry post-translational modification to drive the market for this segment 92
8.3.3.2 Microbial expression systems 93
8.3.3.2.1 Ability of these expression systems to provide high expression levels of proteins to drive the market for this segment 93
8.3.3.3 Yeast expression systems 93
8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand 93
8.3.3.4 Insect expression systems 94
8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand 94
8.3.3.5 Other expression systems 95
9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 96
9.1 INTRODUCTION 97
9.2 PRESCRIPTION DRUGS 98
9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET 98
9.3 OVER-THE-COUNTER DRUGS 99
9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS 99
9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 100
9.4.1 LOW-TO-MODERATE POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 100
9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 101
10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 103
10.1 INTRODUCTION 104
10.2 COMMUNICABLE DISEASES 105
10.2.1 GLOBAL HEALTH IMPACT OF COMMUNICABLE DISEASES AND INCREASING ANTIMICROBIAL RESISTANCE—KEY MARKET DRIVERS 105
10.3 ONCOLOGY 106
10.3.1 INCREASE IN GLOBAL SPENDING ON CANCER MEDICATION TO BOOST THE MARKET FOR THIS SEGMENT 106
10.4 PAIN MANAGEMENT 108
10.4.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET 108

10.5 CARDIOVASCULAR DISEASES 109
10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER 109
10.6 DIABETES 110
10.6.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT 110
10.7 RESPIRATORY DISEASES 111
10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT 111
10.8 OTHER THERAPEUTIC APPLICATIONS 111
11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 113
11.1 INTRODUCTION 114
11.2 NORTH AMERICA 114
11.2.1 US 121
11.2.1.1 Increasing expenditure on medicine is expected to drive the APIs market in the US 121
11.2.2 CANADA 126
11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada 126
11.3 EUROPE 130
11.3.1 GERMANY 137
11.3.1.1 Germany to dominate the market in Europe 137
11.3.2 FRANCE 142
11.3.2.1 Emergence of pharmerging markets in Asia may hinder market growth in France 142
11.3.3 UK 147
11.3.3.1 Growing adoption of generics will drive the growth of the UK market 147
11.3.4 ITALY 152
11.3.4.1 Italy’s share in the global merchant APIs market is expected to remain stable over the forecast period 152
11.3.5 SPAIN 157
11.3.5.1 Spanish market has been typically dominated by branded drugs 157
11.3.6 REST OF EUROPE 162
11.4 ASIA 166
11.4.1 JAPAN 172
11.4.1.1 Japanese government aims to boost the use of generics by 2020 172
11.4.2 CHINA 177
11.4.2.1 Government policies to increase medicine access and affordability will support market growth 177
11.4.3 INDIA 181
11.4.3.1 India is a leading producer of generics 181

11.4.4 SOUTH KOREA 186
11.4.4.1 Government initiatives to introduce full medical coverage for major chronic diseases likely to drive this market 186
11.4.5 REST OF ASIA 190
11.5 REST OF THE WORLD 195
12 COMPETITIVE LANDSCAPE 200
12.1 OVERVIEW 200
12.2 MARKET PLAYER RANKING 202
12.3 COMPETITIVE LEADERSHIP MAPPING 204
12.3.1 VANGUARDS 204
12.3.2 DYNAMIC DIFFERENTIATORS 204
12.3.3 INNOVATORS 204
12.3.4 EMERGING PLAYERS 204
12.4 COMPETITIVE SITUATION AND TRENDS 206
12.4.1 PRODUCT LAUNCHES 206
12.4.2 EXPANSIONS 206
12.4.3 ACQUISITIONS 207
12.4.4 OTHER STRATEGIES 207
13 COMPANY PROFILES 209
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 PFIZER, INC. 209
13.2 NOVARTIS AG 212
13.3 SANOFI 215
13.4 BOEHRINGER INGELHEIM 219
13.5 BRISTOL-MYERS SQUIBB 222
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 226
13.7 ELI LILLY AND COMPANY 229
13.8 GLAXOSMITHKLINE PLC 232
13.9 MERCK & CO., INC. 235
13.10 ABBVIE INC. 238
13.11 F. HOFFMANN-LA ROCHE 242
13.12 ASTRAZENECA 244
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX 246
14.1 DISCUSSION GUIDE 246
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 250
14.3 AVAILABLE CUSTOMIZATIONS 252
14.4 RELATED REPORTS 252
14.5 AUTHOR DETAILS 253

LIST OF TABLES

TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2018 51
TABLE 2 INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL
IN THE US IN 2017–2018 52
TABLE 3 INDICATIVE LIST OF BIOSIMILARS THAT GAINED US REGULATORY
APPROVAL IN 2018 56
TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 60
TABLE 5 INDICATIVE LIST OF NEW MOLECULAR ENTITIES THAT GAINED US FDA APPROVAL IN 2018 61
TABLE 6 LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2018 62
TABLE 7 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2017–2024 (USD BILLION) 62
TABLE 8 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,
2017–2024 (USD BILLION) 63
TABLE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 65
TABLE 10 CAPTIVE API MANUFACTURERS MARKET, BY REGION, 2017–2024 (USD BILLION) 66
TABLE 11 LIST OF SIGNIFICANT CMO/CDMO FACILITY EXPANSIONS 67
TABLE 12 MERCHANT API MANUFACTURERS MARKET, BY REGION,
2017–2024 (USD BILLION) 68
TABLE 13 MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017–2024 (USD BILLION) 68
TABLE 14 MERCHANT INNOVATIVE API MANUFACTURERS MARKET, BY REGION,
2017–2024 (USD BILLION) 69
TABLE 15 MERCHANT GENERIC API MANUFACTURERS MARKET, BY REGION,
2017–2024 (USD BILLION) 70
TABLE 16 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
2017–2024 (USD BILLION) 71
TABLE 17 MERCHANT SYNTHETIC API MANUFACTURERS MARKET, BY REGION,
2017–2024 (USD BILLION) 72
TABLE 18 MERCHANT BIOTECH API MANUFACTURERS MARKET, BY REGION,
2017–2024 (USD BILLION) 73
TABLE 19 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 75
TABLE 20 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,
2017–2024 (USD BILLION) 76
TABLE 21 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
2017–2024 (USD BILLION) 77
TABLE 22 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2017–2024 (USD BILLION) 78
TABLE 23 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2017–2024 (USD BILLION) 79
TABLE 24 TOP SELLING BIOLOGICS (2018) 80
TABLE 25 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,
2017–2024 (USD BILLION) 80
TABLE 26 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 81
TABLE 27 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2017–2024 (USD BILLION) 82
TABLE 28 INDICATIVE LIST OF BIOSIMILARS THAT GAINED US FDA APPROVAL DURING
2017–2018 83
TABLE 29 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2017–2024 (USD BILLION) 84
TABLE 30 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
2017–2024 (USD BILLION) 85
TABLE 31 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL
IN 2018 86
TABLE 32 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2017–2024 (USD BILLION) 86
TABLE 33 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2017–2024 (USD BILLION) 87
TABLE 34 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES,
BY REGION, 2017–2024 (USD BILLION) 88
TABLE 35 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2017–2024 (USD BILLION) 88
TABLE 36 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2017–2024 (USD MILLION) 89
TABLE 37 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2017–2024 (USD MILLION) 90
TABLE 38 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2017–2024 (USD MILLION) 91
TABLE 39 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2017–2024 (USD BILLION) 91
TABLE 40 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2017–2024 (USD BILLION) 92
TABLE 41 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2017–2024 (USD BILLION) 93
TABLE 42 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2017–2024 (USD BILLION) 94
TABLE 43 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2017–2024 (USD BILLION) 95
TABLE 44 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2017–2024 (USD MILLION) 95
TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,
2017–2024 (USD BILLION) 97
TABLE 46 PRESCRIPTION DRUGS MARKET, BY REGION, 2017–2024 (USD BILLION) 98
TABLE 47 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2017-2024 (USD BILLION) 100
TABLE 48 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 102
TABLE 49 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 104
TABLE 50 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR COMMUNICABLE DISEASES (2018) 105
TABLE 51 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2017–2024 (USD BILLION) 106
TABLE 52 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR ONCOLOGY (2018) 107
TABLE 53 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,
BY REGION, 2017–2024 (USD BILLION) 107
TABLE 54 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR PAIN MANAGEMENT (2018) 108
TABLE 55 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT,
BY REGION, 2017–2024 (USD BILLION) 108
TABLE 56 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017–2024 (USD BILLION) 109
TABLE 57 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2017–2024 (USD BILLION) 110
TABLE 58 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2017–2024 (USD BILLION) 111
TABLE 59 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2017–2024 (USD BILLION) 112
TABLE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,
2017–2024 (USD BILLION) 114
TABLE 61 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2017–2024 (USD BILLION) 116
TABLE 62 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 116
TABLE 63 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 116
TABLE 64 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 117
TABLE 65 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 117
TABLE 66 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 118
TABLE 67 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 118
TABLE 68 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 118
TABLE 69 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2017–2024 (USD BILLION) 119
TABLE 70 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF DRUG, 2017–2024 (USD BILLION) 119
TABLE 71 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY POTENCY, 2017–2024 (USD BILLION) 120
TABLE 72 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 120
TABLE 73 INDICATIVE LIST OF RECENT FDA APPROVALS FOR DRUG DELIVERY PRODUCTS 121
TABLE 74 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 122
TABLE 75 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 122
TABLE 76 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 122
TABLE 77 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 123
TABLE 78 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 123
TABLE 79 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 124
TABLE 80 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 124
TABLE 81 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,
2017–2024 (USD BILLION) 124
TABLE 82 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 125
TABLE 83 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 125
TABLE 84 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 126
TABLE 85 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 127
TABLE 86 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 127
TABLE 87 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 127
TABLE 88 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 128
TABLE 89 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 128
TABLE 90 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 129
TABLE 91 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 129
TABLE 92 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 129
TABLE 93 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 130
TABLE 94 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY,
2017–2024 (USD BILLION) 132
TABLE 95 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 132
TABLE 96 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 133
TABLE 97 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 133
TABLE 98 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 133
TABLE 99 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 134
TABLE 100 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 134
TABLE 101 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 135
TABLE 102 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2017–2024 (USD BILLION) 135
TABLE 103 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 136
TABLE 104 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 136
TABLE 105 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 137
TABLE 106 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 138
TABLE 107 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
OF MANUFACTURER, 2017–2024 (USD BILLION) 138
TABLE 108 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 138
TABLE 109 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 139
TABLE 110 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 139
TABLE 111 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 140
TABLE 112 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 140
TABLE 113 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 140
TABLE 114 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017–2024 (USD BILLION) 141
TABLE 115 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 141
TABLE 116 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 142
TABLE 117 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 143
TABLE 118 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 143
TABLE 119 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 144
TABLE 120 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 144
TABLE 121 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 144
TABLE 122 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 145
TABLE 123 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
OF DRUG, 2017–2024 (USD BILLION) 145
TABLE 124 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 146
TABLE 125 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 146
TABLE 126 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 148
TABLE 127 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 149
TABLE 128 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 149
TABLE 129 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 149
TABLE 130 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 150
TABLE 131 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 150
TABLE 132 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 151
TABLE 133 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,
2017–2024 (USD BILLION) 151
TABLE 134 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 151
TABLE 135 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 152
TABLE 136 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 153
TABLE 137 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 153
TABLE 138 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 154
TABLE 139 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 154
TABLE 140 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 154
TABLE 141 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 155
TABLE 142 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 155
TABLE 143 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 156
TABLE 144 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 156
TABLE 145 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 157
TABLE 146 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 158
TABLE 147 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 158
TABLE 148 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 158
TABLE 149 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 159
TABLE 150 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 159
TABLE 151 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 160
TABLE 152 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD MILLION) 160
TABLE 153 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 160
TABLE 154 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD MILLION) 161
TABLE 155 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD MILLION) 161
TABLE 156 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 162
TABLE 157 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 163
TABLE 158 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 163
TABLE 159 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 163
TABLE 160 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 164
TABLE 161 ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 164
TABLE 162 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 165
TABLE 163 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,
2017–2024 (USD BILLION) 165
TABLE 164 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 165
TABLE 165 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 166
TABLE 166 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY,
2017–2024 (USD BILLION) 167
TABLE 167 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 167
TABLE 168 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 168
TABLE 169 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 168
TABLE 170 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 168
TABLE 171 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 169
TABLE 172 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 169
TABLE 173 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 170
TABLE 174 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 170
TABLE 175 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 171
TABLE 176 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 171
TABLE 177 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 172
TABLE 178 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 173
TABLE 179 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 173
TABLE 180 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 173
TABLE 181 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 174
TABLE 182 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 174
TABLE 183 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 175
TABLE 184 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 175
TABLE 185 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 175
TABLE 186 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 176
TABLE 187 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 176
TABLE 188 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 177
TABLE 189 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 178
TABLE 190 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 178
TABLE 191 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 178
TABLE 192 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 179
TABLE 193 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 179
TABLE 194 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 180
TABLE 195 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 180
TABLE 196 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 180
TABLE 197 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 181
TABLE 198 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 182
TABLE 199 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 182
TABLE 200 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 182
TABLE 201 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 183
TABLE 202 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 183
TABLE 203 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 184
TABLE 204 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 184
TABLE 205 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017–2024 (USD BILLION) 184
TABLE 206 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 185
TABLE 207 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 185
TABLE 208 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 186
TABLE 209 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 187
TABLE 210 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 187
TABLE 211 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 187
TABLE 212 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 188
TABLE 213 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 188
TABLE 214 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 189
TABLE 215 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF DRUG, 2017–2024 (USD BILLION) 189
TABLE 216 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY POTENCY, 2017–2024 (USD BILLION) 189
TABLE 217 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 190
TABLE 218 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 191
TABLE 219 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 191
TABLE 220 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 192
TABLE 221 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 192
TABLE 222 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 192
TABLE 223 ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 193
TABLE 224 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 193
TABLE 225 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,
2017–2024 (USD BILLION) 194
TABLE 226 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 194
TABLE 227 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 195
TABLE 228 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2017–2024 (USD BILLION) 196
TABLE 229 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017–2024 (USD BILLION) 196
TABLE 230 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION) 196
TABLE 231 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2017–2024 (USD BILLION) 197
TABLE 232 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION) 197
TABLE 233 ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 198
TABLE 234 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 198
TABLE 235 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
OF DRUG, 2017–2024 (USD BILLION) 198
TABLE 236 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2017–2024 (USD BILLION) 199
TABLE 237 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017–2024 (USD BILLION) 199
TABLE 238 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2018 202
TABLE 239 PRODUCT LAUNCHES, 2016–2018 206
TABLE 240 EXPANSIONS, 2016–2018 206
TABLE 241 ACQUISITIONS, 2015–2018 207
TABLE 242 OTHER STRATEGIES, 2015–2018 207
TABLE 243 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF EUR TO USD) 216
TABLE 244 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD) 233
TABLE 245 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF CHF TO USD) 242


LIST OF FIGURES

FIGURE 1 APIS: MARKET SEGMENTATION 27
FIGURE 2 RESEARCH DESIGN 30
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 34
FIGURE 4 BOTTOM-UP APPROACH 36
FIGURE 5 TOP-DOWN APPROACH 36
FIGURE 6 DATA TRIANGULATION METHODOLOGY 37
FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2019 VS. 2024 (USD BILLION) 39
FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2019 VS. 2024 40
FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,
2019 VS. 2024 40
FIGURE 10 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT,
2019 VS. 2024 41
FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2019 VS. 2024 42
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE ACTIVE PHARMACEUTICAL
INGREDIENTS MARKET 43
FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS ARE DRIVING MARKET GROWTH 44
FIGURE 14 GENERIC APIS TO GROW AT THE HIGHEST CAGR FROM 2019 TO 2024 45
FIGURE 15 MERCHANT API MANUFACTURERS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 45
FIGURE 16 ONCOLOGY SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 46
FIGURE 17 PRESCRIPTION DRUGS TO COMMAND THE LARGEST MARKET SHARE IN 2019 47
FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 47
FIGURE 19 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
FIGURE 20 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT TO DOMINATE THE MARKET IN 2019 60
FIGURE 21 CAPTIVE MANUFACTURERS SEGMENT TO DOMINATE THE MARKET IN 2019 65
FIGURE 22 SYNTHETIC APIS TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING THE FORECAST PERIOD 75
FIGURE 23 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 97
FIGURE 24 LOW-TO-MODERATE SEGMENT TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, IN 2019 101
FIGURE 25 COMMUNICABLE DISEASES TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN 2019 104
FIGURE 26 NORTH AMERICA: MARKET SNAPSHOT 115
FIGURE 27 EUROPE: MARKET SNAPSHOT 131
FIGURE 28 EXPANSIONS—KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO OCTOBER 2018 201
FIGURE 29 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 205
FIGURE 30 PFIZER, INC.: COMPANY SNAPSHOT (2017) 209
FIGURE 31 NOVARTIS AG: COMPANY SNAPSHOT (2017) 212
FIGURE 32 SANOFI: COMPANY SNAPSHOT (2017) 215
FIGURE 33 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017) 219
FIGURE 34 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2017) 222
FIGURE 35 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2017) 226
FIGURE 36 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2017) 229
FIGURE 37 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2017) 232
FIGURE 38 MERCK & CO., INC.: COMPANY SNAPSHOT (2017) 235
FIGURE 39 ABBVIE INC.: COMPANY SNAPSHOT (2017) 238
FIGURE 40 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2017) 242
FIGURE 41 ASTRAZENECA: COMPANY SNAPSHOT (2017) 244


★調査レポート[医薬品有効成分(API)の世界市場予測(~2024年)] ( Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024 / PH 1262) 販売に関する免責事項
[医薬品有効成分(API)の世界市場予測(~2024年)] ( Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024 / PH 1262) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆